General MedicationsINTRAVENOUSGeneric

CUBICIN

DAPTOMYCIN

Standard Dose

250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview CUBICIN is listed in Drugs@FDA under application 021572 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DAPTOMYCIN Form and strength POWDER;INTRAVENOUS - 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2025-05-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview CUBICIN is listed in Drugs@FDA under application 021572 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DAPTOMYCIN Form and strength POWDER;INTRAVENOUS - 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2025-05-12 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.